48 results
8-K
EX-99.1
IMVT
Immunovant Inc
29 May 24
Results of Operations and Financial Condition
4:17pm
environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its
8-K
EX-99.1
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business is heavily
8-K
EX-99.1
wb1ejfq
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
S-3ASR
3d9dml5wq67h9ski0gj
9 Nov 23
Automatic shelf registration
8:49am
8-K
EX-99.1
ah4i bw9w7m
9 Nov 23
Results of Operations and Financial Condition
7:06am
424B5
adkkpx6qjxav
29 Sep 23
Prospectus supplement for primary offering
4:48pm
424B5
k56 3ysdm6u78za
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
ofn1x66rotxppu5192
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
EX-99.1
clb6yrn3h vq7fghb1r
10 Aug 23
Results of Operations and Financial Condition
7:10am
8-K
EX-99.1
ucdb1eviprlyouoa
22 May 23
Results of Operations and Financial Condition
7:03am
424B5
53jluzluqy8q5lra4v71
5 Oct 22
Prospectus supplement for primary offering
4:43pm